LOPINAVIR/RITONAVIR VS GW433908 & RITONAVIR/LOPINAVIR AND GW433908

洛匹那韦/利托那韦 VS GW433908

• 批准号: 7379072
• 负责人: JAMES K RICHARDSON
• 金额: $ 0.07万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7379072
• 关键词: LOPINAVIR; RITONAVIR; VS; GW433908

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A5143 is a selectively randomized, open-label, parallel and comparative study of lopinavir/ritonavir (LPV/RTV) versus GW433908 and ritonavir (GW433908 + RTV) versus lopinavir/ritonavir and GW433908 (LPV/RTV + GW433908) in combination with tenofovir disoproxil fumarate (TDF) and one or two nucleoside reverse transcriptase inhibitors (NRTIs). The primary objective is to compare the safety, efficacy, and tolerability of a combination of ant-HIV drugs in subjects who are infected with the HIV with virologic treatment failure. Subjects will be randomized to one of three treatment arms based on what medications they have taken in the past. All subjects will receive TDF and one or two NRTIs. In addition, those subjects in Arm A will receive lopinavir and ritonavir, those in Arm B will receive GW433908 and ritonavir, and those in Arm C will receive lopinavir, ritonavir, and GW433908. Study participation will be 48 weeks with a total of 216 subjects enrolled. Up to 15 subjects will be enrolled at the IU site. Nine study visits of approximately one hour's duration will be required. Subjects will undergo blood tests to determine CD4 cells and HIV viral loads.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。A5143是一项比较洛匹那韦/利托那韦（LPV/RTV）与GW 433908和利托那韦（GW 433908 + RTV）与洛匹那韦/利托那韦和GW 433908（LPV/RTV + GW 433908）联合富马酸替诺福韦酯（TDF）和一种或两种核苷逆转录酶抑制剂（NRTI）的选择性随机、开放标签、平行和比较研究。主要目的是在病毒学治疗失败的HIV感染受试者中比较抗HIV药物联合治疗的安全性、疗效和耐受性。受试者将根据其过去服用的药物随机分配至三个治疗组之一。所有受试者将接受TDF和一种或两种NRTI。此外，A组受试者将接受洛匹那韦和利托那韦，B组受试者将接受GW 433908和利托那韦，C组受试者将接受洛匹那韦、利托那韦和GW 433908。研究参与期为48周，共入组216例受试者。IU研究中心最多将入组15例受试者。需要进行9次研究访视，每次约1小时。受试者将接受血液检查，以确定CD 4细胞和HIV病毒载量。